Nevro Corp. (1N7.F)

9,70 +0,30 (+3,19%) Börsenschluss: 08:00AM CEST

Nevro Corp.

1800 Bridge Parkway
Redwood City, CA 94065
United States
650 251 0005
https://nevro.com

Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 1.215

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Kevin R. Thornal	President, CEO & Director	1,27M	N/A	1974
Mr. Roderick H. MacLeod	Senior VP & CFO	605,45k	N/A	1967
Mr. Kashif Rashid	Senior VP of Corporate Development & Chief Legal Officer	583,68k	N/A	1974
Mr. Greg Siller	Senior VP & Chief Commercial Officer	389,27k	N/A	1981
Mr. Richard B. Carter	Chief Accounting Officer	N/A	N/A	1971
Mr. Christofer Christoforou	Senior Vice President of Technical Operations	340,6k	N/A	1970
Ms. Angeline C. McCabe	Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Geeta Kaveti	VP and Chief Compliance & Privacy Officer	N/A	N/A	N/A
Meredith Vornholt	Vice President of Global Marketing	N/A	N/A	N/A
Ms. Shana D. Ross M.B.A.	Senior VP & Chief Human Resources Officer	N/A	N/A	1973

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

Corporate Governance

Nevro Corp.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 9. Die grundlegenden Scores sind Audit: 7, Vorstand: 7, Shareholderrechte: 4, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.